Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Neoplasm — Research · CancerIndex

Cancers
Neoplasm

Cancer Family

Neoplasm

CI-CAN-00000001Explore in graph →

Non-malignant22,971 active trials259 approved drugs4,031 evidence items

NCIt: C3262
MeSH: D009369

Overview
Statistics
Survival
Genomics495
Variants & evidence4031
Drugs435
Trials105884
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (4,505)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 4,001–4,025 of 4,505 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis.
· Sci Rep · 2016 · PMID 26786851 · validated civic_curation pubmed
Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice.
· Oncotarget · 2016 · PMID 27049722 · validated civic_curation pubmed
Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.
· Cancer Med · 2015 · PMID 25727400 · validated civic_curation pubmed
Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.
· Cancer Discov · 2013 · PMID 23619167 · validated civic_curation pubmed
PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.
· Anticancer Res · 2013 · PMID 23898052 · validated civic_curation pubmed
Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.
· Pigment Cell Melanoma Res · 2014 · PMID 24495407 · validated civic_curation pubmed
Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer.

Showing 4,001–4,025 of 4,505 publications

← Previous
1
…
160
161
162
…
181
Next →

· Clin Cancer Res · 2011 · PMID 21278246 · validated civic_curation pubmed

The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis.

· Genes Dev · 2012 · PMID 22802530 · validated civic_curation pubmed

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

· Nature · 2012 · PMID 22281684 · validated civic_curation pubmed

Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.

· Clin Cancer Res · 2013 · PMID 23549875 · validated civic_curation pubmed

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

· Cancer Cell · 2004 · PMID 15324695 · validated civic_curation pubmed

Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.

· Clin Cancer Res · 2016 · PMID 26589432 · validated civic_curation pubmed

Elucidating distinct roles for NF1 in melanomagenesis.

· Cancer Discov · 2013 · PMID 23171796 · validated civic_curation pubmed

Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models.

· Clin Cancer Res · 2013 · PMID 23287563 · validated civic_curation pubmed

The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere.

· J Transl Med · 2013 · PMID 24088382 · validated civic_curation pubmed

Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.

· Mol Cancer Ther · 2012 · PMID 22294718 · validated civic_curation pubmed

MEK targeting in N-RAS mutated metastatic melanoma.

· Mol Cancer · 2014 · PMID 24588908 · validated civic_curation pubmed

Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.

· Cancer Cell · 2015 · PMID 25544636 · validated civic_curation pubmed

Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure.

· Oncogene · 2010 · PMID 20473330 · validated civic_curation pubmed

Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts.

· Cancer Res · 2010 · PMID 20354191 · validated civic_curation pubmed

PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.

· Oncogene · 2011 · PMID 21358673 · validated civic_curation pubmed

PI3K pathway dependencies in endometrioid endometrial cancer cell lines.

· Clin Cancer Res · 2013 · PMID 23674493 · validated civic_curation pubmed

LKB1 gene inactivation does not sensitize non-small cell lung cancer cells to mTOR inhibitors in vitro.

· Acta Pharmacol Sin · 2015 · PMID 26027660 · validated civic_curation pubmed

Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin.

· Cancer Res · 2009 · PMID 19706758 · validated civic_curation pubmed

Growth Arrest-Specific 6 (GAS6) Promotes Prostate Cancer Survival by G1 Arrest/S Phase Delay and Inhibition of Apoptosis During Chemotherapy in Bone Marrow.

· J Cell Biochem · 2016 · PMID 27153245 · validated civic_curation pubmed